Thursday, April 10, 2014 Daily Archives

Lonza and AMYRA Sign Comprehensive Development and Manufacturing Services Agreement for Enzyme-Based Treatment of Celiac Disease

Lonza • AMYRA Biotech AG to develop a rational oral treatment for celiac disease using a cocktail of two proprietary enzymes • Contract covers the process development and production of AMYRA’s two enzymes for the treatment of celiac disease • Lonza will develop and manufacture AMYRA’s enzymes in their Kourim, Czech Republic facility • Included in the contract is an XS™ Commercial License with access to Lonza’s XS™ Microbial Expression Technology Platform Basel and Zug, Switzerland, 10 April 2014 –…